Covestor LTD Nektar Therapeutics Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Nektar Therapeutics stock. As of the latest transaction made, Covestor LTD holds 5 shares of NKTR stock, worth $4. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 5 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.9 - $1.83 $18 - $36	-20 Reduced 80.0%	5 $0
Q1 2024 May 10, 2024	SELL	$0.49 - $0.96 $22 - $43	-45 Reduced 64.29%	25 $0
Q4 2023 Feb 09, 2024	SELL	$0.42 - $0.57 $2 - $3	-7 Reduced 9.09%	70 $0
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $5 - $11	-11 Reduced 12.5%	77 $0
Q2 2023 Aug 11, 2023	BUY	$0.53 - $1.03 $30 - $58	57 Added 183.87%	88 $0
Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $4 - $8	-2 Reduced 6.06%	31 $0
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $30 - $51	-10 Reduced 23.26%	33 $0
Q2 2022 Aug 10, 2022	BUY	$3.17 - $6.17 $22 - $43	7 Added 19.44%	43 $0
Q1 2022 May 13, 2022	SELL	$4.16 - $13.72 $24 - $82	-6 Reduced 14.29%	36 $0
Q4 2021 Feb 10, 2022	BUY	$10.83 - $18.41 $454 - $773	42 New	42 $1,000

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account